1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

AZ Looks To Lead Severe Asthma Market After US Fasenra OK

 
• By Kevin Grogan

Following FDA approval, AstraZeneca believes that despite reaching the market after GlaxoSmithKline’s Nucala and Teva’s Cinqair, Fasenra's strong clinical package, convenient dosing and very competitive pricing will make it the leading biologic for severe asthma.

Speedway
AstraZeneca joins the severe asthma race with the US approval of Fasenra • Source: Shutterstock

Days after getting a recommendation for approval in Europe, AstraZeneca PLC has been given the green light in the US to market Fasenra (benralizumab) as a treatment for severe asthma and an alternative to GlaxoSmithKline PLC’s Nucala (mepolizumab) and Teva Pharmaceutical Industries Ltd.'s Cinqair (respizumab).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.